Iovance Biotherapeutics Inc (2LB)

Currency in EUR
2.750
-0.001(-0.02%)
Closed·
2LB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
2LB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.7502.802
52 wk Range
1.43111.600
Key Statistics
Bid/Ask
2.526 / 2.556
Prev. Close
2.751
Open
2.802
Day's Range
2.75-2.802
52 wk Range
1.431-11.6
Volume
1.02K
Average Volume (3m)
4.46K
1-Year Change
-68.15%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2LB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Iovance Biotherapeutics Inc Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Compare 2LB to Peers and Sector

Metrics to compare
2LB
Peers
Sector
Relationship
P/E Ratio
−2.7x−2.7x−0.5x
PEG Ratio
−0.090.010.00
Price/Book
1.3x1.1x2.6x
Price / LTM Sales
4.8x15.3x3.2x
Upside (Analyst Target)
-353.5%41.6%
Fair Value Upside
Unlock22.9%6.0%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.36 / --
Revenue / Forecast
49.32M / --
EPS Revisions
Last 90 days

2LB Income Statement

People Also Watch

14.42
OSCR
-0.21%
51.055
SMR
-1.19%
27.02
CNC
-4.84%
53.810
ASTS
-0.97%
44.570
RKLB
-6.03%

FAQ

What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?

Iovance Biotherapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Iovance Biotherapeutics Inc?

The stock symbol for Iovance Biotherapeutics Inc is "2LB."

What Is the Iovance Biotherapeutics Inc Market Cap?

As of today, Iovance Biotherapeutics Inc market cap is 861.37M.

What Is Iovance Biotherapeutics Inc's Earnings Per Share (TTM)?

The Iovance Biotherapeutics Inc EPS (TTM) is -1.23.

From a Technical Analysis Perspective, Is 2LB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Iovance Biotherapeutics Inc Stock Split?

Iovance Biotherapeutics Inc has split 0 times.

How Many Employees Does Iovance Biotherapeutics Inc Have?

Iovance Biotherapeutics Inc has 838 employees.

What is the current trading status of Iovance Biotherapeutics Inc (2LB)?

As of 28 Jul 2025, Iovance Biotherapeutics Inc (2LB) is trading at a price of 2.75, with a previous close of 2.75. The stock has fluctuated within a day range of 2.75 to 2.80, while its 52-week range spans from 1.43 to 11.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.